DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Phil Skolnick
Phil Skolnick
BMC Pharmacology Biomed Central
Failed Trials for Central Nervous System Disorders Do Not Necessarily
The Opioid Epidemic: Crisis and Solutions
Bfm:978-3-0348-8470-9/1.Pdf
Beyond Monoamine-Based Therapies: Clues to New Approaches
Virginia Drug Discovery Consortium Virginiabrainrx: a Symposium on Drug Discovery for the Brain
Milestones in Drug Therapy
ASPET Preliminary Program for Experimental Biology 2003
Resource List
Pharmacology of Ibogaine and Ibogaine-Related Alkaloids
Elsevier Editorial System(Tm) for Trends in Pharmacological Sciences Manuscript Draft
Ketamine for Treatment-Resistant Depression Sanjay J
Efficacy and Tolerability of the Novel Triple Reuptake Inhibitor Amitifadine
Meeting Announcements
NCDEU 52Nd Annual Meeting an Annual Meeting Sponsored by the American Society of Clinical Psychopharmacology (ASCP)
IMPLEMENTING ANTAGONIST-BASED RELAPSE PREVENTION TREATMENT for OPIOID-DEPENDENT INDIVIDUALS Adam Bisaga M.D
Nnvol23n1.Pdf
An Annual Meeting of the ASCP Recognizing Unmet Needs in Psychopharmacology: from Biomarkers to Breakthrough Therapies
Top View
Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
Dec 06 NUCLEUS Corrected
Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
Differential Responsiveness of Cerebellar Purkinje Neurons to GABA and Benzodiazepine Receptor Ligands in an Animal Model of Hepatic Encephalopathy
Ibogaine As a Glutamate Antagonist: Relevance to Its Putative Antiaddictive Properties
Abstract Book
Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents